SOLAR: A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam (clinicaltrials.gov) - Oct 3, 2026 - P3 | N=90 | Recruiting | Sponsor: Biogen | Initiation date: Apr 2026 ➔ Sep 2026
Trial initiation date • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases • SMN2
|